Regeneron Pharmaceuticals, Inc. and Sanofi have amended their antibody collaboration for Kevzara (sarilumab) and Praluent(alirocumab) by restructuring into a royalty-based agreement. Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent. Regeneron is expected to gain sole U.S. rights to Praluent.
 
Under the proposed terms of the agreement, each party will be solely responsible for funding development and commercialization expenses in their respective territories. These changes are part of an effort to increase efficiency and streamline operations for the products. The existing collaboration relating to Dupixent (dupilumab) remains unchanged. Completion of the proposed agreement is expected to be finalized in 1Q20.